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A B S T R A C T
Introduction: The use of patient-reported outcome measures is increasingly advocated to support high-quality
cancer care. We therefore investigated the added value of the Distress Thermometer (DT) when combined with
known predictors to assess one-year survival in patients with lung cancer.
Methods: All patients had newly diagnosed or recurrent lung cancer, started systemic treatment, and participated
in the intervention arm of a previously published randomised controlled trial. A Cox proportional hazards model
was fitted based on five selected known predictors for survival. The DT-score was added to this model and
contrasted to models including the EORTC-QLQ-C30 global QoL score (quality of life) or the HADS total score
(symptoms of anxiety and depression). Model performance was evaluated through improvement in the -2 log
likelihood, Harrell’s C-statistic, and a risk classification.
Results: In total, 110 patients were included in the analysis of whom 97 patients accurately completed the DT.
Patients with a DT score ≥5 (N=51) had a lower QoL, more symptoms of anxiety and depression, and a shorter
median survival time (7.6 months vs 10.0 months; P=0.02) than patients with a DT score<5 (N=46).
Addition of the DT resulted in a significant improvement in the accuracy of the model to predict one-year
survival (P < 0.001) and the discriminatory value (C-statistic) marginally improved from 0.69 to 0.71. The
proportion of patients correctly classified as high risk (≥85% risk of dying within one year) increased from 8%
to 28%. Similar model performance was observed when combining the selected predictors with QoL and
symptoms of anxiety or depression.
Conclusions: Use of the DT allows clinicians to better identify patients with lung cancer at risk for poor outcomes,
to further explore sources of distress, and subsequently personalize care accordingly.
1. Introduction
Lung cancer is the second most common and deadliest cancer
worldwide. It constitutes approximately 14 percent of all cancer diag-
noses and 27 percent of all cancer deaths [1]. Most patients are diag-
nosed with either locally advanced or metastatic disease and are often
faced with treatment-related toxicities and side-effects [2]. These fac-
tors contribute to a poor prognosis, high levels of distress, and a lower
quality of life (QoL) among patients and their caregivers [3,4].
Despite this poor prognosis and limited survival, many patients with
lung cancer receive aggressive treatments (e.g. chemotherapy) near the
end of their life. Discussions focused on discussing the rationale for such
treatments or patient’s goals and values either happen late in the dis-
ease course or are of insufficient quality [5]. Moreover, it may be dif-
ficult to accurately determine a patient’s prognosis due to the un-
predictability of the disease course. Indeed, previous work shows that
current prognostic predictions by clinicians are frequently inadequate
and largely based on disease-related characteristics [6,7]. Recent stu-
dies have thus suggested that addition of patient-reported outcome
measures (PROMs) to such predictions can be useful to better approx-
imate a patient’s prognosis [8–11]. Use and subsequent discussion of
such measures also leads to better symptom control, increased use of
supportive care facilities or measures, and enhanced patient satisfaction
[12].
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A PROM has been defined as “a measurement of any aspect of a
patient’s health status that comes directly from the patient” [13]. In-
ternational and consensus-based guidelines advocate the routine use of
PROMs as an integral component of high-quality cancer care
[9,11,14–16]. To date however, these measures are only sparsely in-
corporated in clinical care for patients with (lung) cancer [17,18]. One
example of a possibly useful rapid assessment tool is the Distress
Thermometer (DT). The DT is a single-item, visual analogue scale that
can be immediately interpreted to rule out elevated levels of distress in
patients with cancer [19,20]. The prognostic value or significance of
this tool in terms of survival has not been confirmed among patients
with lung cancer [21]. To this end, we sought to investigate the prog-
nostic value of the DT when combined with sociodemographic and
clinical predictors to assess one-year survival in patients with lung
cancer. We also compared this model to models that included quality of
life or symptoms of anxiety and depression.
2. Methods
2.1. Design and setting
This study represents a secondary analysis of data obtained from a
randomised controlled trial (RCT) evaluating the effects of screening for
distress using the DT, the associated Problem List (PL) and additional
supportive care measures to those in need of such care. This study
detailed on the effects of this intervention on QoL, mood, patient sa-
tisfaction, and end-of-life care. The primary results of this trial are
detailed elsewhere [22]. The RCT was conducted at the University
Medical Center Groningen among patients with newly diagnosed or
recurrent lung cancer starting systemic treatment. Randomisation, data
collection and management was performed by the Netherlands Com-
prehensive Cancer Organization. The study was approved by the in-
stitutional Medical Ethics Committee (NTR3540).
In short, patients were included within a week after start of systemic
therapy and subsequently randomized in a 1:1 ratio to either the in-
tervention group or the control group. Only patients assigned to the
intervention group were invited to complete the DT and PL prior to
their scheduled outpatient visit. Dependent on the DT-score, type of
problems identified, and/or patient’s referral wish, responses were
discussed with a nurse practitioner specialized in psychosocial issues.
Patients were subsequently offered referral to an appropriate and li-
censed professional (e.g. a psychologist, social worker, physical thera-
pist, or a dietician). Patients assigned to the control group were not
routinely screened for distress and did not complete the DT and PL.
They received care as usual as determined by the treating clinician. The
primary outcome was the mean change in the EORTC-QLQ-C30 global
QoL-score between 1 and 25 weeks.
2.2. Study population
Between 1 January 2010 and 30 June 2013, 223 patients were
enrolled in the trial (response rate 66%). All patients had received a
histological diagnosis of any type of lung cancer (stage Ib through IV),
had an Eastern Cooperative Oncology Group (ECOG) performance scale
of 0, 1 or 2, had to start a form of systemic treatment, were without
cognitive impairment, and were able to complete questionnaires in
Dutch. Systemic treatment was defined as treatment with che-
motherapy, adjuvant chemotherapy, chemo-radiotherapy, or treatment
with biologicals. Of the patients included, 110 were randomized to the
intervention arm. These patients were asked to complete the DT and
were therefore included in the current analyses.
2.3. Patient characteristics and survival
Sociodemographic characteristics were obtained from the hospital’s
electronic health record at study entry as were clinical characteristics
detailing on histological tumour type, performance status, recurrent
versus new diagnosis, disease stage, initial type of treatment, and the
Charlson age-adjusted co-morbidity index were also derived from the
electronic health record [23]. Date of death was recorded from the
electronic health record up to one year after randomisation.
2.4. Distress thermometer, quality of life, and mood
The DT is an extensively validated measure to screen for distress
[19,24,25]. It consists of a single-item, visual analogue scale with a
score ranging from 0 (no distress) to 10 (extreme distress) and is to be
completed by the patient to quantify the level of distress experience in
the past week. A score on the DT below either four or five, depending
on the country and setting, has been propagated as optimal cut-off to
rule out significant distress in patients with cancer [19,26]. An optimal
cut-off value of five was observed among Dutch patients with cancer
and therefore used in the current study. We did not use data obtained
through the Problem List in these analyses.
All patients also completed the EORTC-QLQ-C30 [27] to assess
health-related QoL and the Hospital Anxiety and Depression Scale
(HADS) [28] to assess mood. Scores on the EORTC-QLQ-C30 may range
from 0 to 100 with higher scores reflecting better QoL. We only used
the global QoL subscale in the current study as a best approximation to
generic QoL. The HADS assesses symptoms of anxiety and depression
over the past week with scores ranging from 0 (not at all) to 3 (very
much). It consists of 14 questions and scores may vary from 0 to 21 with
higher scores indicating more symptoms of anxiety or depression. All
PROMs were completed after patients were randomised but within a
week after the start of systemic therapy.
2.5. Selection of clinical predictors
Candidate predictors for one-year survival were selected based on
the literature as well as expert opinion and availability of such pre-
dictors in clinical settings [29–33]. We selected the following five
clinical or demographic predictors to be included in the model: 1)
gender; 2) performance status (dichotomized as 0 or 1 versus 2);3)
disease stage (dichotomized as non-metastasized: stage I, II and IIIa
versus metastasized: stage IIIb and IV); 4) the Charlson age-adjusted
comorbidity index (entered as a continuous variable) and; 5) tumour
histology (dichotomized as non-small cell lung carcinoma versus small-
cell lung carcinoma).
2.6. Statistical analyses
To characterize the study population, descriptive statistics were
used to evaluate the frequencies, mean, and standard deviations for all
sociodemographic and clinical characteristics as well as other study
measures at study entry. Patients with significant distress (DT-score
≥5) were compared to those without significant distress (DT-score<
5) using independent T-tests and Chi-square tests [26]. The one-year
survival of patients with and without significant distress was compared
with the log-rank test and illustrated with a Kaplan-Meier curve. Sta-
tistical tests were performed with two-sided alternatives and considered
significant if P ≤0.05, using SPSS software version 25 and STATA/IC
version 13.
2.7. Model building
Univariable Cox proportional hazard models were used to de-
termine the association of these predictors separately with one-year
survival. We examined the proportional hazards assumption using log-
minus-log plots. Regardless of statistical significance, all selected pre-
dictors were subsequently entered together simultaneously into a Cox
proportional hazard model. This constituted the basic model. Hereafter,
we separately added three sets of PROMs to the basic model: 1) the DT-
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score; 2) the EORTC-QLQ-C30 global QoL score; and 3) the HADS total
score. We report on the added value of these PROMS to the basic model
by evaluating the change in -2 log likelihood (-2LL), the statistical
significance, and Harrell’s C-statistic with a 95% CI [34]. The -2LL is a
measure of accuracy or overall performance of the model whereas the
C-statistic demonstrates the difference in discriminatory value of a
model comparable to the area under the receiver operating character-
istic curve [34,35].
2.8. Reclassification of high-risk patients
To provide better clinical insight regarding the added value of the
DT, we constructed a reclassification table including all patients who
completed the DT. This table depicts the shift in classification of cases
of mortality and non-cases separately for the basic model and the model
after addition of the DT-score. To obtain this table, the individual
survival risk was calculated for each patient using the baseline survival
and the regression coefficients of the selected predictors. We then de-
fined two risk groups (normal risk vs. high risk) primarily based on the
net one-year survival date of patients with lung cancer. We defined the
high risk group as patients having a one-year mortality risk as ≥85
percent [36,37]. This reclassification was not performed for models that




Relevant demographic and clinical characteristics of the included
patients are displayed in Table 1. Approximately half of these patients
was female (46%), 65% was diagnosed with stage IV lung cancer, and
81% was initially treated with a chemotherapy or chemo-radiotherapy
regimen. A total of 97 patients (88%) accurately completed the DT.
Patients not completing the DT (N=13) were comparable in all so-
ciodemographic as well as clinical characteristics to patients who
completed the DT (all p-values ≥0.10; data not shown).
3.2. Comparison of patients with and without significant distress
Of the 97 patients who accurately completed the DT, 51 had a DT
score> 5 and 46 had a score< 5. Patients with and without significant
distress were comparable in terms of sociodemographic and illness-re-
lated characteristics (Table 1; all p-values ≥0.10). Patients with clini-
cally relevant distress reported a significantly lower global QoL
(p < 0.001), and depicted higher scores on the depression and anxiety
subscales of the HADS as well as the total HADS score (p=0.004;
p=0.004; and p=0.001; respectively). Median one-year survival time
among patients with clinically relevant distress was significantly
shorter: 7.6 months (95% CI: 6.5–8.7) versus 10.0 months (95% CI:
9.1–11.0; P=0.02).
3.3. Univariable analyses and performance of multivariable models
Table 2 displays the univariable relationships between the five se-
lected predictors and the three sets of PROMS with one-year survival.
Performance status, disease stage, and the Charlson age-adjusted co-
morbidity index were all found to be significant predictors. Of the in-
cluded PROMs, the global QoL-score and the DT-score were identified
as significant predictors, but not the HADS.
Table 3 depicts the performance of the multivariable model as well
as the performance of subsequent multivariable models when combined
separately with the three sets of PROMs. The -2LL, i.e. the accuracy of
the model, significantly improved after addition of the global QoL-score
(491.4 to 431.9; P < 0.001), addition of the HADS total score (491.4 to
410.0; P < 0.001), and addition of the DT-score (491.4 to 397.5;
P < 0.001). The C-statistic, i.e. the discriminatory value, improved
slightly from 0.69 (95% CI: 0.63 – 0.76) in the model with clinical
predictors to 0.71 (95% CI: 0.64 – 0.77) after addition of the DT-score.
Addition of the global QoL-score and the HADS total score led to a C-
statistic of 0.69 (95% CI: 0.62 – 0.77) and 0.67 (95% CI: 0.60 – 0.75),
respectively.
3.4. Improved reclassification of high risk patients
The reclassification model of the 97 patients of whom 50 died
within one year is shown in Table 4. The proportion of correctly clas-
sified high-risk patients who died within one year increased from 8
percent to 28 percent (10 additional patients) after addition of the DT-
score to the basic model. Moreover, addition of the DT-score did not
considerably increase the proportion of patients incorrectly classified as
high risk (Table 4; increase from 3% to 5%).
4. Discussion
To our knowledge, this is the first study to show that addition of a
patient-reported distress score, as measured by DT, to selected clinical
predictors may hold prognostic value when estimating one-year sur-
vival. Similar results were obtained when combining the selected pre-
dictors with QoL and symptoms of anxiety or depression. Further, pa-
tients with clinically relevant distress had a significantly shorter median
one-year survival time when compared to patients without clinically
relevant distress, whilst being comparable in terms of clinical and so-
ciodemographic characteristics. This finding was also supported by the
improvement in the classification of patients with a high risk of death
(≥85%) after combining the DT-score with selected predictors. This
suggests that addition of a patient-centered outcome that can be rapidly
interpreted may allow clinicians to more accurately determine which
patients are at risk for a poor prognosis and possibly personalize care
accordingly.
When viewed in the light of current clinical practice, these findings
are important for several reasons. First, we specifically opted to study
the prognostic value of the DT since prognosis of patients with lung
cancer is often poor and the overall one-year net survival is only 30
percent [36,38]. The DT was originally developed as a rapid screening
and diagnostic tool to rule out clinically relevant distress in patients
with cancer [14,25]. Studying the prognostic value of the DT may thus
move this tool beyond the originally intended purpose. Yet, other
PROMs such as QoL, anxiety, and depression have previously been
identified as important prognostic indicators in multiple, large-scale
studies [8–11]. More importantly perhaps, these outcomes are asso-
ciated with distress [39,40]. Having a fast and efficient tool available
that screens for distress, and simultaneously conveys prognostic in-
formation, is therefore a promising finding in this patient population.
Second, numerous studies conducted across different care settings
have provided clear evidence to support the earlier integration of pal-
liative care, sometimes even delivered concurrently with (curative)
treatment [41,42]. This has led to an increased interest with regards to
the earlier integration as well as official endorsement by clinical
guidelines [43]. Yet, many patients with advanced (lung) cancer either
receive such care at a late stage and the quality of such care may not be
optimal [44,45]. Although the use of a short screening tool cannot
substitute careful clinical assessment and management, routine use of
the DT may aid clinicians in identifying those patients at risk for poor
outcomes and provide a vantage point from which to earlier engage
patients and caregivers in patient-centered conversations about
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advance care planning and palliative care options.
In contrast to our findings, one previously conducted study
(N=113) did not identify the prognostic value of the DT in patients
with stage III lung cancer treated with chemotherapy containing car-
boplatin [21]. Notably, the observed median DT-score in that study was
lower compared to the current study and the majority of patients re-
fused to complete the DT and the associated Problem List. As described
by the authors, this selection bias may account for the contrasting
findings. Previous studies, although conducted among different cohorts
of patients with advanced cancer, have shown that screening for dis-
tress has positive effects on the experienced of physical as well as
psychosocial problems [46,47]. Moreover, these studies also observed
that distress measures may convey important prognostic information in
terms of survival.
A recent systematic review concluded that more effort is needed
towards ensuring patients’ adherence when completing PROMs and that
routine completion should be supplemented by clear guidelines to
support clinicians when discussing responses with patients [12]. Other
PROMs such as QoL and anxiety or depression have been found to
convey important prognostic information in patients with cancer
[9,11,16,48]. Yet, these instruments are often lengthy and require ad-
ditional training and time investment. Also, healthcare professionals
have cited practical concerns related to the length of questionnaires and
required time investment, disruption of workflow, costs, and a lack of
training for accurate interpretation [49]. In contrast to this, the DT
allows for rapid assessment and may therefore be easier to integrate in
clinical settings.
Our findings should be viewed in light of certain limitations. The
Table 1








Age (mean ± SD) 60.6 ± 10.5 59.8 ± 10.5 61.3 ± 10.7















Recurrent disease, yes (N
[%])
29 (26) 9 (20) 16 (31)
Disease stage (N [%])
Stage 1 or 2































































Characteristic Total study population (N=110) DT-score < 5
(N=46)a




Global quality of life (N=94)
59.2 ± 20.8 69.4 ± 19.1 51.5 ± 17.3***





















Abbreviations: DT: Distress Thermometer, SD: Standard Deviation.
*p< 0.05, ** p< 0.01, ***P< 0.001, otherwise not significant (p> 0.10).
a Patients below the DT-score cutoff and DT-score above cutoff were compared. The remaining 13 patients did not accurately complete the DT and could not be
included in this analysis.
b The 30-item EORTC-QLQ-C30 assesses QOL. Scores can range from 0 to 100 with higher scores reflecting better functioning.
c The 14-item Hospital Anxiety and Depression Scale (HADS) assesses anxiety and depression levels over the last week in two subscales each consisting of seven
items. Scores vary from 0 to 21 with higher scores indicating greater anxiety or depression.
d Number of respondents vary and are denoted per questionnaire or subscale.
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current study represents a secondary analysis of a previously conducted
RCT at a single, academic institution and our sample size was small.
Further, although we did include patients with any histological subtype
of lung cancer and all patients started a form of systemic treatment,
only patients with an ECOG performance status between 0 and 2 were
eligible for inclusion in the trial (the full score ranges from 0 to 5).
These observations limit the generalizability of our findings. Third, the
current patient population does not include patients treated with im-
munotherapy. This recent treatment modality is likely to markedly shift
the prognosis of patients with advanced lung cancer in the near future.
It would therefore be interesting to investigate whether patients with
increased levels of distress are also at risk of a poor prognosis among
those patients treated with immunotherapy.
Next, we used the -2LL and the C-statistic as a best approximation to
general performance of the different multivariable models. The -2LL did
show significant improvements after addition of the different PROMs
but we did not observe similar findings using the C-statistic (all values
between 0.67 and 0.71). The C-statistic, however, has been criticized
for a lack of sensitivity with regards to recognizing the added value of a
risk marker. It has therefore been recommended to additionally con-
struct and report on a reclassification table since this conveys important
complementary information [50]. In line with this, we decided to use a
cutoff of 85 percent to define patients at high risk of dying within one
year [36,37]. We specifically decided not to include the EORTC-QLQ-
C30 or the HADS in this reclassification table. Instead, we contrasted
the performance of these PROMs in the outlined multivariable models
to demonstrate similar performance of the DT when compared to other
PROMs.
Further, although this cutoff likely represents the futility of further
tumor-targeted treatment in this patient population, it was arbitrarily
chosen and should be further validated in future studies. Last, the re-
sponse rate in the original trial was relatively low (66%). This was most
likely because of the high symptom burden these patients already face
and was also stated as the most common reason for participation refusal
(41% of objectors). This should be taken into consideration when in-
terpreting our current findings.
4.1. Conclusions
In conclusion, this is the first study to provide evidence for added
prognostic value of the DT-score in patients with lung cancer. The pos-
sible relationship between the DT-score and survival should be evaluated
further in prospective, longitudinal studies across different settings and
institutions [9]. Yet, our findings are promising and may allow clinicians
to identify those patients at risk for poor outcomes and prevent dis-
cordance between care received and personal patient preferences near
the end of life. This may further improve the timely delivery of high
quality, patient-centered care among patients with lung cancer.
Fig. 1. Kaplan-Meier overall one-year survival curve stratified by
significantly elevated elevated distress as evaluated by the Distress
Thermometer (cutoff score of 5). Survival data was calculated from the
date of randomization and date of death was recorded up to one year
later.
Table 2
Univariable associations of selected clinical predictors with one-year survival.
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Global quality of life scale
−0.15 0.99 (0.97 – 1.0) 0.02
Hospital Anxiety and Depression
scale
Total score
0.013 1.01 (0.98 – 1.05) 0.32
Distress Thermometer
Total score
0.21 1.24 (1.09 – 1.40) 0.001
a: Reference category The Hazard Ratio is displayed per unit of the score for
continuous variables.
Table 3
Different multivariable models of selected predictors when combined with various patient-reported outcome measures.
Variables included in model −2 LL P-value C-statistic (95% CI)
Selected predictors (N=110) 491.4 – 0.69 (0.63 – 0.76)
Selected predictors +
global Quality of Life (N=99)
431.9 <0.001 0.69 (0.62 – 0.77)
Selected predictors +
symptoms of anxiety and depression (N=96)
410.0 <0.001 0.67 (0.60 – 0.75)
Selected predictors +
Distress Thermometer score (N=97)
397.5 <0.001 0.71 (0.64 – 0.77)
P-value calculated (Chi-square two-sided test) versus model with selected predictors only.
Abbreviations: -2 LL: -2 Log Likelihood. C-statistic: Harrel’s C concordance statistic The five selected predictors1) gender, 2) performance status at inclusion, 3)
disease stage, 4) Charlson age-adjusted comorbidity score, 5) histology.; Global Quality of Life was measured using the global QoL subscale of the EORTC-QLQ-
C30. Symptoms of anxiety and depression were measured using the Hospital Anxiety and Depression Scale total score.
Table 4
Improved predicted one-year mortality risk classification with addition of the
Distress Thermometer score to selected predictors among 97 patients with lung
cancer.
Predicted risk of mortality within one year Yes, N (%) No, N (%) Total
Selected predictors
Normal risk < 85% 46 (92) 46 (97) 92
High risk ≥85% 4 (8) 1 (3) 5
Total risk group 50 (100) 47 (100) 97
Selected clinical predictors+Distress Thermometer score
Normal risk < 85% 36 (72) 45 (95) 81
High risk ≥85% 14 (28) 2 (5) 16
Total risk group 50 (100) 47 (100) 97
The five selected predictors: 1) gender, 2) performance status at inclusion, 3)
disease stage, 4) Charlson age-adjusted comorbidity score, 5) histology.
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